Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats

European Neuropsychopharmacology

Volumn 16, Issue 8, 2006, Pages 561-571

  Qu, Ying ^a   Chang, Lisa ^a   Klaff, Justin ^a   Seemann, Ruth ^a   Greenstein, Deanna ^b   Rapoport, Stanley I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

5 HT2A 2C; Arachidonic; Depression; Fluoxetine; Phospholipase A2; Rat; Receptor; Serotonin

Indexed keywords

ARACHIDONIC ACID; FLUOXETINE; PROPYLAMINE; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; ENZYME ACTIVATION; KAPPA STATISTICS; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; UPREGULATION;

AMPHETAMINES; ANIMALS; ARACHIDONIC ACID; AUTORADIOGRAPHY; BRAIN; BRAIN MAPPING; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUOXETINE; INFUSIONS, INTRAVENOUS; MALE; RATS; RATS, INBRED F344; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; TRITIUM; UP-REGULATION; WAKEFULNESS;

EID: 33750806781     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.01.008     Document Type: Article

References (76)

1. Aghajanian G.K., and Marek G.J. Serotonin and hallucinogens. Neuropsychopharmacology 21 (1999) 16S-23S
2. Amsterdam J.D., Garcia-Espana F., Fawcett J., Quitkin F.M., Reimherr F.W., Rosenbaum J.F., Schweizer E., and Beasley C. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J. Clin. Psychopharmacol. 18 (1998) 435-440
3. Ashby Jr. C.R., Jiang L.H., Kasser R.J., and Wang R.Y. Electrophysiological characterization of 5-hydroxytryptamine2 receptors in the rat medial prefrontal cortex. J. Pharmacol. Exp. Ther. 252 (1990) 171-178
4. Axelrod J. Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction. Biochem. Soc. Trans. 18 (1990) 503-507
5. Basselin M., Chang L., Seemann R., Bell J.M., and Rapoport S.I. Chronic lithium administration to rats selectively modifies 5-HT2A / 2C receptor-mediated brain signaling via arachidonic acid. Neuropsychopharmacology 30 (2005) 461-472
6. Bazinet, R.P. Unpublished results.
7. Bazinet R.P., Rao J.S., Chang L., Rapoport S.I., and Lee H.J. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol. Psychiatry (2005) (Sept. 20)
8. Bengel D., Murphy D.L., Andrews A.M., Wichems C.H., Feltner D., Heils A., Mossner R., Westphal H., and Lesch K.P. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol. Pharmacol. 53 (1998) 649-655
9. Berg K.A., Maayani S., Goldfarb J., and Clarke W.P. Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Ann. N.Y. Acad. Sci. 861 (1998) 104-110
10. Bhattacharjee A.K., Chang L., Lee H.J., Bazinet R.P., Seemann R., and Rapoport S.I. D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats. Psychopharmacology 180 (2005) 735-742 (Berl)
11. Blier P., and de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1 (1987) 470-480
12. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15 (1994) 220-226
13. Boerlin H.L., Gitlin M.J., Zoellner L.A., and Hammen C.L. Bipolar depression and antidepressant-induced mania: a naturalistic study. J. Clin. Psychiatry 59 (1998) 374-379
14. Bymaster F.P., Zhang W., Carter P.A., Shaw J., Chernet E., Phebus L., Wong D.T., and Perry K.W. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology 160 (2002) 353-361 (Berl)
15. Caccia S., Cappi M., Fracasso C., and Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 100 (1990) 509-514 (Berl)
16. Cadogan A.K., Marsden C.A., Tulloch I., and Kendall D.A. Evidence that chronic administration of paroxetine or fluoxetine enhances 5-HT2 receptor function in the brain of the guinea pig. Neuropharmacology 32 (1993) 249-256
17. Calabrese J.R., Rapport D.J., Kimmel S.E., and Shelton M.D. Controlled trials in bipolar I depression: focus on switch rates and efficacy. Eur. Neuropsychopharmacol. 9 4 (1999) S109-S112
18. Chang M.C.J., Grange E., Rabin O., Bell J.M., Allen D.D., and Rapoport S.I. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci. Lett. 220 (1996) 171-174
19. 11C]-arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography. Brain Res. 755 (1997) 74-83
20. Cooper J.R., Bloom F.E., and Roth R.H. The Biochemical Basis of Neuropharmacology (2003), Oxford University Press, Oxford 404
21. Czachura J.F., and Rasmussen K. Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naunyn-Schmiedebergs Arch. Pharmacol. 362 (2000) 266-275
22. Damjanoska K.J., Van De Kar L.D., Kindel G.H., Zhang Y., D'Souza D.N., Garcia F., Battaglia G., and Muma N.A. Chronic fluoxetine differentially affects 5-hydroxytryptamine(2A) receptor signaling in frontal cortex, oxytocin and corticotropin releasing factor containing neurons in rat paraventricular nucleus. J. Pharmacol. Exp. Ther. 306 (2003) 563-571
23. DeGeorge J.J., Nariai T., Yamazaki S., Williams W.M., and Rapoport S.I. Arecoline-stimulated brain incorporation of intravenously administered fatty acids in unanesthetized rats. J. Neurochem. 56 (1991) 352-355
24. DeMar Jr. J.C., Ma K., Bell J.M., and Rapoport S.I. Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n - 3 polyunsaturated fatty acids. J. Neurochem. 91 (2004) 1125-1137
25. Dennis E.A. Diversity of group types, regulation, and function of phospholipase A2. J. Biol. Chem. 269 (1994) 13057-13060
26. el Mansari M., Bouchard C., and Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology 13 (1995) 117-127
27. Folch J., Lees M., and Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226 (1957) 497-509
28. Freo U., Soncrant T.T., Holloway H.W., and Rapoport S.I. Dose- and time-dependent effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a serotonergic 5-HT2 receptor agonist, on local cerebral glucose metabolism in awake animals. Brain Res. 541 (1991) 63-69
29. Freo U., Ori C., Dam M., Merico A., and Pizzolato G. Effects of acute and chronic treatment with fluoxetine on regional glucose cerebral metabolism in rats: implications for clinical therapies. Brain Res. 854 (2000) 35-41
30. Fuller R.W. Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Prog. Drug Res. 45 (1995) 167-204
31. Fuller R.W., and Wong D.T. Inhibition of serotonin reuptake. Fed. Proc. 36 (1977) 2154-2158
32. Garcia M.C., and Kim H.Y. Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. Brain Res. 768 (1997) 43-48
33. Ghelardoni S., Tomita Y.A., Bell J.M., Rapoport S.I., and Bosetti F. Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol. Psychiatry 56 (2004) 248-254
34. Go F.S., Malley E.E., Birmaher B., and Rosenberg D.R. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 8 (1998) 73-80
35. Gobbi M., Crespi D., Foddi M.C., Fracasso C., Mancini L., Parotti L., and Mennini T. Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats. Naunyn-Schmiedebergs Arch. Pharmacol. 356 (1997) 22-28
36. Hensler J.G. Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 26 (2002) 565-573
37. Hrdina P.D., and Vu T.B. Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study. Synapse 14 (1993) 324-331
38. Invernizzi R., Bramante M., and Samanin R. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol. Biochem. Behav. 54 (1996) 143-147
39. 3H]arachidonic acid from blood into rat brain synaptosomal fractions before and after cholinergic stimulation. J. Neurochem. 67 (1996) 822-829
40. Kanterman R.Y., Mahan L.C., Briley E.M., Monsma Jr. F.J., Sibley D.R., Axelrod J., and Felder C.C. Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Mol. Pharmacol. 39 (1991) 364-369
41. Kucia K., Malecki A., Gabryel B., and Trzeciak H.I. Effect of antidepressants on the phospholipase A2 activity in plasma membranes of the rat brain cortex. Pol. J. Pharmacol. 55 (2003) 5-15
42. Kurrasch-Orbaugh D.M., Parrish J.C., Watts V.J., and Nichols D.E. A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J. Neurochem. 86 (2003) 980-991
43. Le Poul E., Boni C., Hanoun N., Laporte A.M., Laaris N., Chauveau J., Hamon M., and Lanfumey L. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 39 (2000) 110-122
44. Lee H., Villacreses N.E., Rapoport S.I., and Rosenberger T.A. In vivo imaging detects a transient increase in brain arachidonic acid metabolism: a potential marker of neuroinflammation. J. Neurochem. 91 (2004) 936-945
45. Li Q., Muma N.A., and van de Kar L.D. Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist. J. Pharmacol. Exp. Ther. 279 (1996) 1035-1042
46. Li Q., Wichems C.H., Ma L., Van de Kar L.D., Garcia F., and Murphy D.L. Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J. Neurochem. 84 (2003) 1256-1265
47. Mathews T.A., Fedele D.E., Coppelli F.M., Avila A.M., Murphy D.L., and Andrews A.M. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J. Neurosci. Methods 140 (2004) 169-181
48. McKenna D.J., Nazarali A.J., Hoffman A.J., Nichols D.E., Mathis C.A., and Saavedra J.M. Common receptors for hallucinogens in rat brain: a comparative autoradiographic study using [125I]LSD and [125I]DOI, a new psychotomimetic radioligand. Brain Res. 476 (1989) 45-56
49. Muthalif M.M., Benter I.F., Uddin M.R., and Malik K.U. Calcium/calmodulin-dependent protein kinase II alpha mediates activation of mitogen-activated protein kinase and cytosolic phospholipase A2 in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells. J. Biol. Chem. 271 (1996) 30149-30157
50. Newman M.E., Shalom G., Ran A., Gur E., and Van de Kar L.D. Chronic fluoxetine-induced desensitization of 5-HT1A and 5-HT1B autoreceptors: regional differences and effects of WAY-100635. Eur. J. Pharmacol. 486 (2004) 25-30
51. Ng N.K., Lee H.S., and Wong P.T. Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors. J. Neurosci. Res. 55 (1999) 600-607
52. Pavoine C., Magne S., Sauvadet A., and Pecker F. Evidence for a beta2-adrenergic/arachidonic acid pathway in ventricular cardiomyocytes. Regulation by the beta1-adrenergic/camp pathway. J. Biol. Chem. 274 (1999) 628-637
53. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1987), Academic Press, New York
54. Pazos A., and Palacios J.M. Quantitative autoradiographic mapping of serotonin receptor in the rat brain: I. Serotonin-1 receptors. Brain Res. 346 (1985) 205-230
55. Qu Y., Chang L., Klaff J., Balbo A., and Rapoport S.I. Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (±)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI). Neuropsychopharmacology 28 (2003) 244-252
56. Qu Y., Chang L., Klaff J., Seemann R., and Rapoport S.I. Imaging brain phospholipase A2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats. Neuropsychopharmacology 28 (2003) 1219-1226
57. Qu Y., Villacreses N., Murphy D.L., and Rapoport S.I. 5-HT(2A / 2C) receptor signaling via phospholipase A(2) and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacology (Berl) 180 (2005) 12-20
58. Rapoport S.I. In vivo fatty acid incorporation into brain phospholipids in relation to plasma availability, signal transduction and membrane remodeling. J. Mol. Neurosci. 16 (2001) 243-261
59. Rapoport S.I. Quantifying and imaging brain arachidonic and docosahexaenoic acid metabolism in vivo. J. Pediatr. 143 (2003) S26-S33
60. Rapoport S.I., and Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?. Arch. Gen. Psychiatry 59 (2002) 592-596
61. Rapoport S.I., Chang L., Klaff J., Seemann R., and Qu Y. Chronically administered fluoxetine increased phospholipase A2-mediated incorporation of arachidonic acid into brain of anesthetized rat. Abstr. 42nd Ann. Mtg. Amer. Coll. Neuropsychopharm vol. 42 (2003), PR, San Juan 191-192 December 7-11
62. Rintala J., Seemann R., Chandrasekaran K., Rosenberger T.A., Chang L., Contreras M.A., Rapoport S.I., and Chang M.C. 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 10 (1999) 3887-3890
63. Robinson P.J., Noronha J., DeGeorge J.J., Freed L.M., Nariai T., and Rapoport S.I. A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis. Brain Res. Rev. 17 (1992) 187-214
64. Rosenberger T.A., Villacreses N.E., Hovda J.T., Bosetti F., Weerasinghe G., Wine R.N., Harry G.J., and Rapoport S.I. Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide. J. Neurochem. 88 (2004) 1168-1178
65. Rutter J.J., Gundlah C., and Auerbach S.B. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci. Lett. 171 (1994) 183-186
66. Schmidt M.J., Fuller R.W., and Wong D.T. Fluoxetine, a highly selective serotonin reuptake inhibitor: a review of preclinical studies. Br. J. Psychiatr., Suppl. 3 (1988) 40-46
67. Sokoloff L. Energetics of functional activation in neural tissues. Neurochem. Res. 24 (1999) 321-329
68. Staley J.K., Malison R.T., and Innis R.B. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol. Psychiatry 44 (1998) 534-549
69. Stenfors C., and Ross S.B. Evidence for involvement of 5-hydroxytryptamine(1B) autoreceptors in the enhancement of serotonin turnover in the mouse brain following repeated treatment with fluoxetine. Life Sci. (2002) 2867-2880
70. Stenfors C., and Ross S.B. Evidence for involvement of protein kinases in the regulation of serotonin synthesis and turnover in the mouse brain in vivo. J. Neural Transm. 109 (2002) 1353-1363
71. Sublette M.E., Russ M.J., and Smith G.S. Evidence for a role of the arachidonic acid cascade in affective disorders: a review. Bipolar Disord. 6 (2004) 95-105
72. Szabo S.T., and Blier P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology 25 (2001) 845-857
73. Tilakaratne N., Yang Z., and Friedman E. Chronic fluoxetine or desmethylimipramine treatment alters 5-HT2 receptor mediated c-fos gene expression. Eur. J. Pharmacol. 290 (1995) 263-266
74. Vial D., and Piomelli D. Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonic-specific phospholipase A2. J. Neurochem. 64 (1995) 2765-2772
75. Wong D.T., Bymaster F.P., and Engleman E.A. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 57 (1995) 411-441
76. Xu T., and Pandey S.C. Cellular localization of serotonin(2A) (5HT(2A)) receptors in the rat brain. Brain Res. Bull. 51 (2000) 499-505